Profile data is unavailable for this security.
About the company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
- Revenue in USD (TTM)0.00
- Net income in USD-42.44m
- Incorporated2019
- Employees67.00
- LocationAlto Neuroscience Inc369 South San Antonio Rd.LOS ALTOS 94022United StatesUSA
- Phone+1 (773) 255-5012
- Fax+1 (302) 655-5049
- Websitehttps://www.altoneuroscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | 38.30m | -134.81m | 314.47m | 123.00 | -- | 11.24 | -- | 8.21 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Candel Therapeutics Inc | 0.00 | -37.37m | 314.70m | 42.00 | -- | 51.93 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 315.91m | 5.50k | 5.38 | 8.02 | 4.53 | 0.7629 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 321.34m | 137.00 | -- | 2.54 | -- | 3.56 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -163.66m | 321.73m | 74.00 | -- | 0.6379 | -- | -- | -1.96 | -1.96 | 0.00 | 5.99 | 0.00 | -- | -- | 0.00 | -27.48 | -5.90 | -28.78 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -90.25m | 322.00m | 88.00 | -- | 1.51 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 329.58m | 74.00 | -- | 1.07 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 330.14m | 67.00 | -- | 1.71 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -37.50m | 336.25m | 11.00 | -- | 4.26 | -- | -- | -4.50 | -4.50 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -75.43 | -232.67 | -101.00 | -- | -- | -- | -- | -- | -- | -46.11 | 0.0552 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| AC Immune SA | 16.17m | -59.23m | 342.23m | 133.00 | -- | 1.95 | -- | 21.17 | -0.701 | -0.701 | 0.1904 | 1.77 | 0.0803 | -- | 1.92 | 121,544.00 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Foghorn Therapeutics Inc. | 33.90m | -92.95m | 344.14m | 116.00 | -- | -- | -- | 10.15 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 346.98m | 163.00 | -- | 1.39 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.58m | 347.05m | 140.00 | -- | 2.19 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Precigen Inc | 5.44m | -96.91m | 348.34m | 202.00 | -- | 3.56 | -- | 64.04 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Sutro Biopharma Inc | 154.07m | -114.96m | 348.44m | 300.00 | -- | 2.71 | -- | 2.26 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 349.56m | 44.00 | -- | 0.9871 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Alto Neuroscience Inc's reporting currency: US Dollar USD
47.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alpha Wave Global LPas of 31 Mar 2024 | 3.71m | 13.79% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.35m | 8.74% |
| Point72 Asset Management LPas of 31 Mar 2024 | 1.79m | 6.67% |
| RA Capital Management LPas of 31 Mar 2024 | 1.39m | 5.15% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 637.60k | 2.37% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 625.01k | 2.33% |
| ExodusPoint Capital Management LPas of 31 Mar 2024 | 606.73k | 2.26% |
| Deep Track Capital LPas of 31 Mar 2024 | 600.00k | 2.23% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 530.54k | 1.97% |
| Jennison Associates LLCas of 31 Mar 2024 | 458.60k | 1.71% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
